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Melanoma progresses as a multistep process where
the thickness of the lesion and depth of tumor invasion
are the best prognostic indicators of clinical outcome.
Degradation of the interstitial collagens in the extracel-
lular matrix is an integral component of tumor invasion
and metastasis, and much of this degradation is medi-
ated by collagenase-1 (MMP-1), a member of the matrix
metalloproteinase (MMP) family. MMP-1 levels increase
during melanoma progression where they are associ-
ated with shorter disease-free survival. The Ras/Raf/
MEK/ERK mitogen-activated protein kinase (MAPK)
pathway is a major regulator of melanoma cell prolifer-
ation. Recently, BRAF has been identified as a common
site of activating mutations, and, although many reports
focus on its growth-promoting effects, this pathway has
also been implicated in progression toward metastatic
disease. In this study, we describe four melanoma cell
lines that produce high levels of MMP-1 constitutively.
In each cell line the Ras/Raf/MEK/ERK pathway is con-
stitutively active and is the dominant pathway driving
the production of MMP-1. Activation of this pathway
arises due to either an activating mutation in BRAF
(three cell lines) or autocrine fibroblast growth factor
signaling (one cell line). Furthermore, blocking MEK/
ERK activity inhibits melanoma cell proliferation and
abrogates collagen degradation, thus decreasing their
metastatic potential. Importantly, this inhibition of in-
vasive behavior can occur in the absence of any detect-
able changes in cell proliferation and survival. Thus,
constitutive activation of this MAPK pathway not only
promotes the increased proliferation of melanoma cells
but is also important for the acquisition of an invasive
phenotype.
Melanoma, like other malignant cancers, progresses as a
multistep process that can be classified histologically, with the
depth of tumor invasion being the best prognostic indicator of
clinical outcome (1–3). Invasive melanomas are clinically ag-
gressive and prone to metastasis, leading to disseminated dis-
ease (4, 5). Multiple stages leading to metastatic disease have
been described; however, the transition from the radial growth
phase (RGP)1 to the vertical growth phase (VGP) stands out as
a particularly biologically and clinically important step (3). As
a rule, RGP melanomas grow in a plane parallel with the skin’s
surface and are not capable of metastasizing. Largely, they
remain within the epidermis, and have only very limited der-
mal infiltration. In contrast, VGP melanomas grow perpendic-
ular to the skin’s surface and are able to metastasize. They can
invade deeply into the underlying dermis, which is composed of
numerous structural obstacles, the most prevalent being type I
collagen. The molecular events underlying the acquisition of
vertical growth and of a metastatic phenotype are of obvious
importance and are being actively investigated (3, 6–8).
Tumor invasion and metastasis require proteolytic degrada-
tion of the basement membrane and extracellular matrix
(ECM) by the matrix metalloproteinases (MMPs). MMP ex-
pression is low in most normal cells under physiologic condi-
tions, however, MMP expression is dramatically increased in a
variety of cancer types, where it is indicative of invasive dis-
ease with a poor clinical prognosis (4, 5, 9–12). One MMP
family member capable of degrading the most abundant pro-
teins of the ECM (collagen types I and III) is the interstitial
collagenase, MMP-1. MMP-1 is overexpressed in invasive mel-
anoma (5, 9) and is required for melanoma cell invasion
through a synthetic ECM in vitro (13).
In normal cells, MMP-1 expression can be induced by a
variety of growth factors, including bFGF, epidermal growth
factor, interleukin-1, and tumor necrosis factor  (14). This
induction requires the activation of the mitogen-activated pro-
tein kinase (MAPK) pathways, which in turn act in part
through activation of AP-1 and ETS family transcription fac-
tors (14–19). There are at least three major human MAPK
families: the extracellular response kinases (ERKs), p38, and
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Jun N-terminal kinases (JNKs) (20). Specific pharmacologic
inhibitors of these MAPK pathways, such as U0126, which
blocks the phosphorylation and activation of MEK1/2 (the up-
stream activators of ERK1/2) and SB203580, which inhibits the
kinase activity of p38, have been useful in analyzing the role of
MAPK pathways in transcriptional activation of MMP-1 in
normal cells, including fibroblasts and chondrocytes (14). Al-
though most reports conclude that ERK and p38 MAPK acti-
vation can induce MMP-1 in response to various stimuli (14, 17,
21–24), p38 activity can also inhibit MMP-1 induction in some
situations (23, 25). Similar opposing differences in the regula-
tion of MMP-1 by different MAPK cascades have been de-
scribed in tumor cells (reviewed in Ref. 26), however, the bulk
of this literature focuses on cells treated with inductive agents
(27, 28). Much less is known about the regulatory mechanisms
underlying high constitutive MMP-1 production by trans-
formed cells.
The Ras/Raf/MEK/ERK MAPK pathway is constitutively ac-
tive in most melanomas, where it is an important regulator of
proliferation and survival (reviewed in Ref. 29). ERK activation
in these cells can arise due to either autocrine growth factor
stimulation or mutational activation of components of the Ras/
Raf/MEK/ERK pathway itself (30). Recent reports have identi-
fied BRAF as a common site of activating mutations in greater
than 66% of samples tested, with 80–90% of these mutations
occurring at residue 599 (V599E) (31–35). Although many re-
ports have focused on its growth-promoting and transformation
activities (31, 36), BRAF lesions were found in only 10% of the
earliest stage RGP melanomas, whereas 60–70% of invasive
VGP and metastatic tumors contained the mutation, arguing
that it is associated with tumor progression, rather than initi-
ation (37). Additional studies have confirmed that BRAF mu-
tation is more frequently acquired during the development of
metastasis, rather than in the initiation of primary disease (38,
39), and inhibitors of the Raf/MEK/ERK pathway are actively
being explored as a potential therapeutic target (40, 41).
We report here that MMP-1 is constitutively produced in four
invasive melanoma cell lines and that this high level of expres-
sion is dependent on Raf/MEK/ERK activation. The constitu-
tive activation of the ERK pathway and the production of
MMP-1 arise due to either a V599E BRAF-activating mutation
(three cell lines) or autocrine FGF signaling (one cell line).
Although the p38 inhibitor SB203580 also decreases MMP-1
production in two of the cell lines, we present evidence that this
inhibition is an indirect effect mediated by inhibition of the
MEK/ERK pathway by SB203580. Furthermore, inhibiting
MEK/ERK decreases both cell proliferation and collagenolytic
activity in vitro. Importantly, however, inhibition of MMP-1
production and subsequent collagen breakdown can occur in
the absence of any detectable changes in cell survival. We
conclude that, along with its importance in melanoma prolifer-
ation and transformation, the Ras/Raf/MEK/ERK pathway is
the driving force behind the overexpression of MMP-1 in inva-
sive cells. Thus, constitutive activation of this pathway allows
melanoma cells to grow autonomously and to acquire an inva-
sive phenotype, thereby facilitating metastasis.
EXPERIMENTAL PROCEDURES
Reagents and Plasmids—The MEK1/2 inhibitor U0126 and the p38
inhibitor SB203580 were purchased from Calbiochem, and stock solu-
tions were made in Me2SO at 1000 the final working concentration. In
each experiment, cells treated with Me2SO (final concentration, 0.1%)
served as a vehicle control. The 4.4-kb human MMP-1 promoter/lucif-
erase construct has been described elsewhere (42). A truncated, domi-
nant negative FGFR1 (FGFR-DN) construct (43) was kindly provided
by Dr. Robert Friesel (Maine Medical Research Institute), and the
constitutively active MKK3(Glu) expression construct (44) was pro-
vided by Dr. Roger Davis (University of Massachusetts Medical School).
The dominant negative RAF (Raf-N4) encodes the tandem Ras-binding
domains (RBD and CRD; residues 23–284) of c-Raf in the expression
vector pGCN-hygro (45), and the constitutively active human BRAF
(V599E) construct was cloned into the pBABE Puro expression
plasmid.2
Cell Culture—A2058 cells were purchased from ATCC. VMM5,
VMM12, and VMM39 melanoma cells were initially isolated from
lymph node metastasis from three separate patients at the University
of Virginia, Charlottesville, VA. The cells were propagated in 150-mm
diameter culture dishes in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) containing 10% fetal bovine serum, penicillin (100
units/ml), and streptomycin (100 g/ml) (37 °C in 5% CO2). After 3–4
days, when the cells were confluent, they were passaged 1:10 with
0.25% trypsin. In experiments performed under serum-free conditions,
cells were grown to the desired level of confluence, washed with Hanks’
balanced salt solution (Invitrogen) to remove traces of serum, and
placed in serum-free DMEM supplemented with 0.2% lactalbumin
hydrolysate.
Western Blot Analysis—For analysis of total and phosphorylated
MAPK proteins, duplicate wells of melanoma cells were washed with
Hanks’ balanced salt solution and then scraped in 2 denaturing SDS
buffer. Extracts were heated for 10 min at 100 °C and resolved by
SDS-PAGE and immunoblotted as described previously (16, 18). Anti-
bodies to p38, pp38, MEK1/2, ppMEK1/2, pp42/44, and p42/44 were
purchased from Cell Signaling.
Northern Blot Analysis—Confluent cultures of melanoma cells were
placed in serum-free medium for 24 h. Total RNA was harvested with
TRIzol (Invitrogen). RNA (10 g/lane) was subjected to electrophoresis
on 1% formaldehyde agarose gels and transferred to a GeneScreen
Plus membrane. Membranes were hybridized with denatured
[-32P]dCTP-cDNAs for MMP-1, labeled by random oligonucleotide
priming, and exposed to x-ray film overnight.
Real-time RT-PCR—Total cellular RNA was harvested using the
RNeasy kit (Qiagen) and subjected to on-column DNase treatment as
per the manufacturer’s instructions. RT and real-time PCR were per-
formed using protocols and reagents from Applied Biosystems Taqman
RT reagent kit and Sybr Green PCR master mix as described (16).
Briefly, 2 g of DNase-treated RNA was reverse-transcribed in a 20-l
reaction containing 5.5 mM MgCl2, 500 M each dNTP, 2.5 M oligonu-
cleotide d(T)16, 0.4 unit/l RNase inhibitor, and 1.25 unit/l Multiscribe
reverse transcriptase. The reactions were incubated at 25 °C for 5 min,
48 °C for 30 min, and then 95 °C for 5 min. Five microliters of each RT
reaction was used to amplify each mRNA in triplicate real-time PCR
reactions. To enable quantitative comparisons between PCR assays,
standard curves were generated with every assay. Serial log dilutions
ranging from 1 ng to 100 fg of American Type Culture Collection
plasmids pSP6-MMP-1 and pCMV sport6 were used as standards for
MMP-1 and GAPDH, respectively. Sequences for the MMP-1 primers
were 5-AGCTAGCTCAGGATGACATTGATG-3 (sense) and 5-GC-
CGATGGGCTGGACAG-3 (antisense); and GAPDH primers were 5-
CGACAGTCAGCCGCATCTT-3 (sense) and 5-CCCCATGGTGTCT-
GAGCG-3 (antisense). The PCRs contained 200 nM of each primer and
were incubated on a Molecular Dynamics Opticon thermal cycler at
95 °C for 10 min, followed by 40 PCR cycles of 95 °C for 15 s, and 60 °C
for 1 min, and a plate read. The PCR cycles were followed by a Sybr
green melting curve from 55 to 90 °C. MMP-1 mRNA expression was
normalized to GAPDH mRNA expression and is reported as mean
copies of MMP-1 message per picogram of GAPDH.
Transient Transfections—Triplicate cultures of melanoma cells were
plated at a density of 3  105 cells per well in 6-well tissue culture
plates and transfected with LipofectAMINE 2000TM transfection rea-
gent (Invitrogen) as per the manufacturer’s instructions. The next day,
cells were placed in serum-free medium, and in some experiments,
treated with MAPK inhibitors or Me2SO vehicle control. After 8 h, cells
were washed three times with phosphate-buffered saline and lysed in
1 Passive Lysis Buffer (Promega). Luciferase activity was measured
and reported as relative light units. For co-transfection studies involv-
ing MAPK mutants, the total amount of DNA was kept constant by the
addition of the appropriate empty vector control, and the mean of the
empty vector control values for each cell line was set arbitrarily at 100
to facilitate the graphical display of multiple cell lines in the same
chart.
Collagen Degradation Assay—Fibrillar collagen was prepared from
bovine type I collagen (Vitrogen 100, Cohesion Technologies, Palo Alto,
2 H. Hao, V. M. Muniz-Medina, K. Frantz, H. Mehta, N. E. Thomas,
C. J. Der, and J. M. Shields, manuscript in preparation.
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CA) as described by the manufacturer. Briefly, the collagen was neu-
tralized by the addition of 10 phosphate-buffered saline and 0.1 N
NaOH until the final pH reached 7.4. Next, 2  105 melanoma cells
suspended in 0.5 ml of serum-free DMEM were mixed with 0.5 ml of the
neutralized collagen solution and added to one well of a 6-well plate
(final collagen concentration is 1.2 mg/ml). Plates were then transferred
to a 37 °C tissue culture incubator for at least 1 h to promote collagen
gel formation. One ml of serum-free DMEM plus any treatment was
then added to the collagen gel (1 mm thick) with embedded cells. After
48 h, the overlying medium was removed and weighed. Finally, side-
view photographs of the remaining collagen gel were taken. All exper-
iments were done in triplicate.
Cell Number Assays—Parallel cultures of melanoma cells (350,000
cells per well) were plated in DMEM with 10% serum and allowed to
adhere overnight. After 16 h, the cells were washed and switched to
serum-free DMEM with U0126 (5 M) or Me2SO. Cells were harvested
by trypsin digestion and counted at the times indicated. All experi-
ments were performed in triplicate.
Statistical Analysis—All numerical values reported represent mean
values  S.D. Statistical significance compared with control values was
calculated using the Student’s t test available at www.physics.csbsju.
edu/stats/. Asterisks were used to graphically denote statistical signif-
icance (p  0.05) in the figures.
RESULTS
Inhibition of MAPK Pathways Decreases the High Constitu-
tive Expression of MMP-1 in VMM and A2058 Melanoma
Cells—As a first step in defining the molecular mechanisms
underlying MMP-1 expression in invasive melanoma, we chose
four melanoma cell lines and measured MMP-1 mRNA produc-
tion in each cell line by Northern blot analysis (Fig. 1A) and
real-time RT-PCR (Fig. 1B). In each cell line, MMP-1 mRNA
expression was constitutively high, and greatly exceeded the
level of expression of MT1-MMP, MMP-2, MMP-3, MMP-9, and
MMP-13 (Ref. 16 and data not shown). We have previously
reported that ERK is constitutively active in the VMM5 and
A2058 cells, and that MMP-1 expression is decreased in cells
treated with an inhibitor of the ERK pathway (16, 19, 46). To
investigate if this observation could be extended to the other
melanoma cells, we first measured ERK activity in VMM12
and VMM39 cells cultured in serum-free conditions and found
that both cell lines display constitutively active ERK, which
can be inhibited by treatment with 5 M of the MEK1/2 specific
inhibitor U0126 (Fig. 1C).
Next we treated cells with U0126 (5 M) and measured
MMP-1 mRNA by real-time RT-PCR 18 h later. Fig. 2A shows
a statistically significant (p  0.0001) decrease (70%) in
MMP-1 mRNA levels in both the VMM12 and VMM39 cells
after U0126 treatment. Since we have previously reported that
VMM5 melanoma cells also rely on the p38 pathway for MMP-1
production (16), we investigated whether the other VMM mel-
anoma cell lines utilize this pathway as well. Fig. 2B shows
dose-response curves of MMP-1 mRNA levels in VMM12 and
VMM39 cells treated with the p38 inhibitor SB203580. Similar
to the VMM5 cells (16), VMM12 cells show a significant dose-
dependent decrease in MMP-1 mRNA when treated with 5 and
10 M SB203580, whereas the VMM39 cells show a modest but
significant (p  0.03) induction of MMP-1. These changes in
mRNA were mirrored in secreted MMP-1 protein levels as
measured by Western blot analysis of precipitated culture me-
dium (Fig. 2C). To determine if the effects of U0126 and
SB203580 occurred at the level of gene transcription, we tran-
siently transfected both the VMM12 and VMM39 cells with a
luciferase reporter construct driven by 4.4 kb of the human
MMP-1 promoter. Both inhibitors decreased MMP-1 promoter
activity in the VMM12 cells, while U0126 decreased, and
SB203580 increased MMP-1 in the VMM39 cells (Fig. 2D).
Similar to previous studies with the VMM5 and A2058 cells
(16, 19, 46), these findings parallel those obtained for the
endogenous gene, arguing that both U0126 and SB203580 ex-
ert their inhibitory effects at the level of transcription.
SB203580 Decreases MEK and ERK Activity in VMM5 and
VMM12, but Not VMM39 Cells—Because considerable cross-
talk occurs among different MAPK pathways (25, 47–49), we
investigated the effect of p38 inhibition on the activation of
MEK and ERK. Each VMM cell line was treated with 10 M
SB203580 for 18 h, and protein lysates were subjected to West-
ern blot analysis for phosphorylated (active) MEK1/2 and
ERK1/2 as well as total ERK1/2. In each cell line, MEK and
ERK are constitutively active (Fig. 3). In the VMM39 cells,
SB203580 treatment induced ERK1/2 and MEK1/2 activity,
consistent with other published reports that the p38 pathway
can act as a negative regulator of MEK/ERK signaling (48, 49).
However, in the VMM5 and VMM12 cells, the opposite effect
was observed: SB203580 caused a substantial decrease in phos-
pho-MEK and ERK levels (Fig. 3A). In the VMM12 cells, this
inhibitory effect was rapid (within 15 min of treatment), pro-
longed (significant up to 25 h) (Fig. 3B), and was observed at
concentrations as low as 5 M (data not shown).
Sodium Arsenite Activation of ERK, but Not p38, Induces
MMP-1 mRNA in VMM Cells—Given the inhibitory effects of
SB203580 on the ERK pathway in VMM5 and VMM12 cells, it
is possible that SB203580 decreased MMP-1 production indi-
rectly through its effects on MEK/ERK. To test this hypothesis,
we investigated whether MMP-1 production could be induced
by ERK and/or p38 activation. One agent known to induce
FIG. 1. Melanoma cell lines express high levels of MMP-1 and
have active ERK1/2 constitutively. Total RNA and cellular lysates
were isolated from VMM5, VMM12, VMM39, and A2058 melanoma
cells cultured in serum-free DMEM. A, RNA (10 g) was subjected to
Northern blot analysis, and MMP-1 mRNA levels were measured in
each cell line. B, quantification of MMP-1 mRNA levels in VMM mela-
noma cell lines measured by real-time RT-PCR. Values are given as
molecules of MMP-1 mRNA per picogram of GAPDH. C, total cellular
lysates from VMM12 and VMM39 melanoma cells treated for 16 h with
U0126 as indicated and subjected to Western blotting for total ERK1/2
and phospho-ERK1/2.
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multiple MAPK pathways, including p38 and ERK, is sodium
arsenite (25, 49–51). Therefore, we treated the VMM12 and
VMM39 cells with 20 M sodium arsenite and measured the
time course of both ERK and p38 activation. Phospho-p38 was
virtually undetectable in the untreated cells but increased sub-
stantially in the first hour after arsenite treatment (Fig. 4A).
Arsenite treatment also strongly induced ERK phosphorylation
in both cell lines within 30 min (Fig. 4A). Induction of both p38
and ERK was sustained, persisting for at least 8 h. Based on
these results, we next treated each cell line with 20 M sodium
arsenite and measured MMP-1 mRNA levels by real-time RT-
PCR after 8 h. To assess the contribution of each MAPK path-
way, we also included experimental groups treated with the
p38 inhibitor SB203580 (10 M) and the MEK inhibitor U0126
(5 M). We found that arsenite induces MMP-1 mRNA in both
the VMM12 (Fig. 4B) and VMM39 cells (Fig. 4C), and this
induction can be blocked by the addition of U0126. However,
treatment with SB203580 cannot block the arsenite-mediated
induction of MMP-1 in either cell line. Taken together, these
data show that the MEK/ERK pathway, but not the p38 path-
way, is capable of inducing MMP-1, and argue in favor of ERK
playing a dominant role in the constitutive production of
MMP-1 in these cells.
Overexpression of Constitutively Active BRAF but Not MKK3
Activates MMP-1 Promoter Activity in VMM Melanoma
Cells—To further analyze the ability of the p38 and ERK path-
ways to induce MMP-1, we overexpressed two constitutively
active upstream components of these two pathways (MKK3
and BRAF) by transient transfection and measured MMP-1
promoter activity. When constitutively active MKK3, an up-
stream inducer of p38 activity, was overexpressed, it had no
effect on MMP-1 in the VMM12 cells at any concentration
tested (Fig. 5A). In the VMM39 cells, only the highest concen-
tration (1 g) had a modest inhibitory effect (Fig. 5A), illustrat-
ing that, in these cells, p38 activity is actually a negative
regulator of MMP-1. In contrast, activating the MEK/ERK
pathway by overexpressing an activated BRAF mutant signif-
icantly increased MMP-1 promoter activity in a dose-depend-
FIG. 2. MMP-1 levels are decreased in VMM12 and VMM39 cells treated with MAPK inhibitors. A, VMM12 and VMM39 cells cultured
in serum-free DMEM were treated with U0126 (5 M) or Me2SO vehicle control for 16 h. Total RNA was isolated, and MMP-1 mRNA levels were
measured by real-time RT-PCR. Values are mean molecules of MMP-1 per picogram of GAPDH  S.D. B, real-time RT-PCR of MMP-1 mRNA
(mean molecules of MMP-1/pg of GAPDH  S.D.) in VMM12 and VMM39 cells cultured in serum-free DMEM treated with the p38 inhibitor
SB203580 (5 and 10 M) or Me2SO for 16 h. C, VMM12 and VMM39 cells were cultured in serum-free DMEM with either Me2SO, U0126 (5 M),
or SB203580 (10 M). After 16 h, culture medium was harvested, centrifuged to pellet cellular debris, and trichloroacetic acid-precipitated. Protein
pellets were resuspended in reducing SDS loading buffer and subjected to SDS-PAGE analysis, followed by Western blotting for MMP-1 protein.
D, VMM12 and VMM39 cells were transiently transfected with 1 g of the 4.4-kb human MMP-1 promoter and after an overnight recovery in
serum containing medium, the cells were washed, and treated for 8 h with serum-free DMEM containing Me2SO, U0126 (5 M), or SB203580 (10
M). The cells were lysed in passive lysis buffer, and luciferase activity was measured. All experiments were done in triplicate and reported as mean
RLU  S.D.
FIG. 3. SB203580 treatment decreases MEK/ERK activity in
VMM5 and VMM12 but increases in VMM39 cells. A, VMM cells
were cultured in serum-free DMEM and treated with SB203580 (10 M)
or vehicle as indicated. After 12 h, the cells were lysed in reducing SDS
loading buffer and subjected to Western blotting with anti-phospho
MEK (top panel), anti-phospho ERK1/2 (middle panel), or total ERK1/2
(lower panel) antibodies. B, VMM12 cells were treated with SB203580
(10 M) for the times indicated, after which, the cells were lysed in
reducing SDS loading buffer and subjected to Western blotting with
anti-phospho ERK1/2 (top panel) or total ERK1/2 (lower panel)
antibodies.
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ent manner (Fig. 5B) in both the VMM12 and VMM39 cells.
Thus, MMP-1 is induced by MEK/ERK, but not p38 activation
in these cells, further implicating the RAF/MEK/ERK pathway
in the regulation of MMP-1.
VMM Cells Utilize Different Means to Activate the Raf/MEK/
ERK Pathway and to Induce MMP-1 Production—A growing
body of evidence indicates that the ERK pathway plays a cru-
cial role in the pathogenesis of melanoma (reviewed in Ref. 29).
In the majority of melanomas, constitutive activation of this
pathway arises from activating mutations in exon 15 of the
BRAF gene. Therefore, we PCR-amplified and sequenced this
region using previously published primers (52). Table I shows
the sequence of nucleotides 1857–1867 for each cell line. Se-
quence analysis shows a single-base nucleotide (A to T) substi-
tution at nucleotide 1860 in the A2058, VMM5, and VMM12,
but not VMM39 cells. This nucleotide substitution results in
the V599E activating mutation and, thus, can explain the con-
stitutive activation of the ERK pathway in these cells. To
identify the mechanism of ERK activation and subsequent
MMP-1 production in the VMM39 cells, we overexpressed a
truncated mutant of c-RAF (c-RAF4N), which blocks Ras func-
tion by antagonizing its interaction with wild-type Raf (45) and
measured MMP-1 promoter activity (Fig. 6A). In the presence
of c-RAF4N overexpression, MMP-1 was decreased in the
VMM39 cells, indicating that even though they lack the V599E
activating mutation, Ras/Raf activity is essential for MMP-1
expression in these cells. In the VMM12 cells, which do not
require Ras activation of Raf, because they have the
V599EBRAF mutation, c-RAF4N overexpression had no signifi-
cant effect on MMP-1.
Constitutive ERK activation may also arise due to autocrine
growth factor production by melanoma cells (30). One factor
that has received considerable attention is basic fibroblast
growth factor (bFGF) (53–57), a potent inducer of the Ras/Raf/
MEK/ERK pathway and MMP-1 transcription in other cell
types (15, 21). Thus, we tested whether MMP-1 production in
the VMM39 cells was dependent on FGF signaling by overex-
pressing a truncated, dominant negative form of the FGF re-
ceptor (FGFR-DN) and measuring MMP-1 promoter activity.
Fig. 6B shows that with increasing amounts of FGFR-DN,
there is a dose-dependent decrease in MMP-1 promoter activity
in the VMM39 cells, arguing that in these cells MMP-1 produc-
tion is dependent on autocrine FGF signaling. In contrast, no
inhibition of MMP-1 is seen in the V599EBRAF-positive VMM5
or VMM12 cells. Interestingly MMP-1 is actually induced with
FGFR-DN overexpression in the VMM12 cells indicating that
in these cells autocrine FGF signaling exerts a negative influ-
ence on MMP-1 expression. The signaling events contributing
FIG. 4. Sodium arsenite activation of MEK/ERK, but not p38,
induces MMP-1 mRNA. A, VMM12 and VMM39 cells were cultured in
serum-free DMEM treated with sodium arsenite (20 M) for the times
indicated. The cells were then lysed in reducing SDS loading buffer and
subjected to Western blotting with anti-phospho ERK1/2 (top panel) or
anti-phospho p38 (lower panel) antibodies. VMM12 (B) and VMM39 (C)
cells in serum-free DMEM were treated with a combination of sodium
arsenite (20 M) and either U0126 (5 M), SB203580 (10 M), or Me2SO
vehicle control for 8 h as indicated. Total RNA was isolated, and MMP-1
mRNA levels were measured by real-time RT-PCR. Values are reported
in percentage of Me2SO control (mean  S.D.). *, p  0.05 compared
with Me2SO control values; #, p  0.05 compared with Me2SO plus
arsenite.
FIG. 5. Overexpression of activated BRAF but not MKK3 in-
duces MMP-1 in VMM melanoma cells. VMM cells were co-trans-
fected with 1 g of the 4.4-kb human MMP-1 promoter luciferase
reporter and increasing amounts of activated MKK3 (A) or activated
(V599E) BRAF (B). In each case the total amount of DNA transfected
per well was kept constant at 2 g by the addition of the appropriate
empty vector construct. After an overnight recovery in serum-contain-
ing medium, the cells were washed, and switched to serum-free DMEM
for 8 h. At this time, the cells were lysed in passive lysis buffer, and
luciferase activity was measured. All experiments were done in tripli-
cate and reported as mean RLU  S.D.
TABLE I
Sequence of nucleotides 1857–1867 of exon 15 of
BRAF gene for each cell line
Sequence data for each cell line was obtained as described under
“Experimental Procedures.” The A to T nucleotide substitution at posi-
tion 1860 results in the V599EBRAF-activating mutation.
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to this negative regulation are not known, and given that
VMM12 cells continue to express MMP-1 at high levels despite
the presence of this autocrine, inhibitory effect, we believe that
it is of relatively little functional importance.
MEK Inhibition Decreases Both Melanoma Proliferation and
Collagenolytic Activity in Vitro—To investigate whether the
U0126-mediated decrease in MMP-1 expression was function-
ally significant, we chose the two cell lines exhibiting the high-
est MMP-1 production (A2058 and VMM12) and measured
their ability to digest a synthetic type I collagen matrix in vitro.
After embedding in fibrillar collagen, A2058 and VMM12 cells
were treated with U0126 or Me2SO vehicle control and incu-
bated at 37 °C for 48 h. Fig. 7A shows that neither A2058 nor
VMM12 cells treated with U0126 were able to digest the type I
collagen, whereas little or no collagen remained in the wells
treated with Me2SO. We quantified the amount of collagen
digested by collecting and weighing the culture medium from
each well. Because 1 ml (1 g) of medium was added to each well
at the time of collagen gel composition, the recovery of more
than 1 g of medium indicates that collagen breakdown has
occurred due to the liberation of medium, which had previously
been contained within the collagen gel. Fig. 7B shows the mean
weight of medium collected for each cell line treated with
U0126 or Me2SO. In both cell lines, 1 ml (1 g) of medium was
recovered from wells treated with U0126, whereas greater
quantities were recovered from wells receiving Me2SO treat-
ment, indicating that MEK/ERK inhibition resulted in signifi-
cant (p  0.0001 for A2058; p  0.002 for VMM12) abrogation
of collagen degradation.
Because the RAF/MEK/ERK pathway has been implicated in
melanoma survival and proliferation (29, 36, 40), we examined
the effect of MEK inhibition on cell growth. Equal numbers of
VMM5, VMM12, VMM39, and A2058 cells were plated in se-
rum-containing medium. After 16 h, the cells were switched to
serum-free DMEM and treated with either Me2SO or U0126
and allowed to grow for an additional 48 h. Cells from each well
were trypsinized and counted. Fig. 7C shows the cell numbers
for each cell line treated with Me2SO vehicle or U0126. Both
the VMM5 and VMM12 cell numbers were significantly (p 
0.001) affected by MEK inhibition, with each cell line showing
75% fewer cells after 48 h of treatment. In contrast, VMM39
and A2058 cell proliferation were largely unaffected, suggest-
ing that other growth-promoting pathways are also active in
these cells. It is noteworthy that, in the A2058 cells, MEK/ERK
inhibition by U0126 completely prevented collagen digestion
yet had no significant effect on cell survival or proliferation.
Because U0126 treatment decreased the cell number in the
VMM12 cells, and this difference could influence collagenolytic
activity as measured by our degradation assay, we examined
the effect of U0126 treatment on cell proliferation more closely.
Fig. 7D shows the kinetics of the change in VMM12 cell number
after treatment with either Me2SO or U0126. At the start of
treatment, each well averaged 300,000 cells, and this number
was not significantly changed in either treatment group after
24 h. After 48 h of treatment, there were 440,000 more cells
in the Me2SO-treated wells as compared with the U0126 wells
(605,000 and 164,000, respectively), however, most of this dif-
ference arose due to the continued proliferation of Me2SO-
treated cells (net increase of 325,000 cells) as compared with
the death of U0126-treated cells (net decrease of 116,000 cells).
Although we can clearly not comment on the mechanism un-
derlying the decrease in cell number after U0126 treatment, it
stands to reason that if the inhibitory effect of U0126 on colla-
gen degradation was due to the decreased number of cells,
rather than to a decrease in MMP-1 production, simply plating
more cells in the U0126-treated wells should result in signifi-
cant collagen degradation. However, this was found not to be
the case, because collagenolytic activity was not restored in
U0126-treated cells even when the number of cells was in-
creased 4-fold (Fig. 7E). Thus, the decrease in collagen degra-
dation by U0126 treatment can not be explained simply by its
effects on cell number and most likely is a direct result of
U0126 inhibition of MMP-1 production.
DISCUSSION
In melanoma, multiple stages leading to metastatic disease
have been described, however, the transition from nonmeta-
static RGP to metastatically competent VGP stands out as a
particularly important step, biologically and clinically (3). Be-
cause MMPs are critical facilitators of tumor invasion, their
expression patterns have been studied during different stages
of melanoma progression and found to be temporally and spa-
tially regulated (9, 12). These expression patterns suggest that
specific MMPs contribute to specific stages in melanoma pro-
gression, with the interstitial collagenase MMP-1 being ex-
pressed in later, more invasive tumors (9). Given the mounting
evidence that MMP-1 is an important player in tumor progres-
sion (reviewed in Ref. 10) and that inhibiting MMP-1 produc-
tion in melanoma cells decreases the invasive potential of mel-
anoma cells (13), we have begun to investigate the molecular
pathways underlying the constitutive expression of MMP-1 by
melanoma cells (16, 19).
In the present study we report that MMP-1 production in
four different melanoma cell lines depends upon the activity of
the RAF/MEK/ERK MAPK pathway. Treating these cells with
the MEK inhibitor U0126 decreases both MMP-1 mRNA and
protein levels. Because U0126 also decreases MMP-1 promoter
activity, this inhibition is most likely occurring at the level of
transcription. Conversely, overexpression of an activated mu-
tant of BRAF (V599E) further induces MMP-1. Inhibiting
MEK/ERK activity and MMP-1 production with U0126 com-
pletely prevented collagen digestion by both the VMM12 and
A2058 cells embedded in type I collagen. These results parallel
those reported in another study in which melanoma cell inva-
sion through Matrigel was found to be decreased with MEK/
ERK inhibition (58) and underscore the importance of this
MAPK pathway in the development of an invasive phenotype.
FIG. 6. MMP-1 production by VMM39 cells relies on FGFR
function and Ras. VMM cells were co-transfected with 1 g of the
4.4-kb human MMP-1 promoter and increasing amounts of (A)
C-RAF4N or (B) FGFR-DN. In each case the total amount of DNA
transfected per well was kept constant by the addition of the appropri-
ate empty vector construct. After an overnight recovery in serum-
containing medium, the cells were washed, and switched to serum-free
DMEM for 8 h. At this time, the cells were lysed in passive lysis buffer,
and luciferase activity was measured. All experiments were done in
triplicate and reported as mean RLU  S.D.
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Our initial data indicated that MMP-1 production is de-
creased due to p38 inhibition by SB203580 (16). We can now
report that the p38 pathway, when activated by either sodium
arsenite or overexpression of an activated mutant of MKK3, is
unable to induce MMP-1. Thus, the effect of SB203580 is most
likely indirect, given that SB203580 treatment also decreases
MEK/ERK activity. Whether this inhibition is a direct effect of
SB203580 on MEK/ERK, or an indirect effect arising due to p38
inhibition remains to be determined; however, there are reports
of SB203580 acting as a modulator of RAF activity (59, 60).
Our finding that constitutive MMP-1 production and MEK/
ERK activity are associated with either an activating mutation
in exon 15 of the BRAF gene or autocrine FGF signaling is
consistent with previously published reports (29, 30). It inter-
esting to note that, in our small sampling of melanoma cell
lines, the three lines that have the V599EBRAF mutation
(A2058, VMM5, and VMM12), all produce substantially more
MMP-1 than the VMM39 cells, which rely on autocrine FGF
signaling. Furthermore, when the V599EBRAF mutant is over-
expressed in the VMM39 cells, MMP-1 induction is more ro-
bust, with a greater relative -fold induction than in either the
VMM5 or VMM12 cells. Taken together, these observations
suggest that direct activation of BRAF is a more efficient
means of activating MEK/ERK and its downstream effectors
than indirectly activating the pathway via an autocrine growth
factor loop, and may help to explain why such a high percent-
age of melanomas harbor BRAF mutations.
In this study we focused on MMP-1, because it was the most
abundantly expressed MMP with activity against the type I
and III collagen molecules found in the dermal ECM. Each of
the cell lines also produced MT1-MMP, a MMP that has been
implicated in playing an important role in collagenolysis and
tumor cell invasion (61). Although MT1-MMP expression has
also been shown to depend on MEK/ERK activity in other
FIG. 7. MEK/ERK inhibition by U0126 decreases VMM cell proliferation and collagenolytic activity. A2058 or VMM12 melanoma cells
were embedded in purified bovine type I collagen and 1 ml of serum-free DMEM with either Me2SO or U0126 (5 M) was added to each well. After
48 h, all overlying medium was removed and weighed, and the underlying collagen gel was photographed. A, side-view image of a tissue culture
plate showing collagen gel thickness after 48 h for A2058 (upper panel) and VMM12 cells (lower panel). Arrows indicate the lower and upper gel
boundaries. B, mean weight (in grams  S.D.) of overlying medium. Greater than 1 g (1 ml) of recovery indicates collagen degradation has occurred
due to the liberation of medium from the gel. C, equal numbers of each cell line were plated in serum-containing DMEM and allowed to adhere
overnight. The next morning, triplicate wells were switched to serum-free DMEM treated with U0126 (5 M) or Me2SO. After 48 h, the cells were
harvested by trypsin digestion and counted (values are mean number of cells  S.D.). D, VMM12 cells were plated in triplicate in DMEM with 10%
serum and allowed to adhere overnight. After 16 h, the cells were washed and switched to serum-free DMEM with U0126 (5 M) or Me2SO. Cells
were harvested by trypsin digestion and counted at the times indicated. Values reported are the mean number of cells per well  S.D. E, VMM12
cells were embedded in collagen at three different densities (1X, 2X, and 4X) and treated with either U0126 (5 M) or Me2SO as indicated. After
48 h, the overlying medium was removed and weighed. Values are mean weight in grams  S.D.
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tumor cell types (62), we observed no inhibition of MT1-MMP
expression upon U0126 treatment (data not shown). Although
we can not comment on the overall contribution of MT1-MMP
to facilitating melanoma cell invasion, in this study, changes in
type I collagenolytic activity did not correlate with changes in
MT1-MMP expression.
Given our previous observations regarding the crucial role of
stromal-derived proteases in facilitating melanoma invasion
when A2058 cells were plated on top of collagen gels (63), we
were intrigued by the ability of both the A2058 and VMM12
cells to digest type I collagen in the absence of either stromal
cells or conditioned medium when directly embedded in a col-
lagen matrix. This robust destruction of the collagen gel by the
embedded cells (Fig. 7), but not the surface-plated cells (63),
underscores the differences between a two-dimensional (cells
plated on top) and a three-dimensional (cells embedded) envi-
ronment. Identifying the factors induced by this three-dimen-
sional environment, and the signaling mechanisms underlying
this induction are currently being addressed.
The question of when BRAF mutations occur during mela-
noma progression continues to be an area of active investiga-
tion and debate (32–35, 37–39, 52, 64–66), yet some common
themes are emerging. BRAF mutations are more frequently
found in metastatic disease as compared with primary mela-
noma and despite reports implicating BRAF mutation as an
important facilitator of melanoma transformation and prolifer-
ation (31, 36), several studies have concluded that BRAF mu-
tation correlates most closely with melanoma progression and
the development of metastasis (37–39, 64). Our findings are
consistent with this conclusion, given our data showing that
U0126 treatment significantly affects the cell number in only
two of the four melanoma cell lines we examined, but decreases
MMP-1 production in all four cell lines (Fig. 1 and Ref. 16).
Furthermore, even in cases when MEK/ERK inhibition does
not decrease cell proliferation (such as in the A2058 cells),
U0126 treatment abrogates the ability of these cells to digest
collagen, and thus, may decrease their malignant potential.
In summary, we demonstrated that, in four different mela-
noma cell lines, the expression of MMP-1, a protein implicated
in melanoma invasion and progression, relies upon MEK/ERK
activity either due to BRAF-activating mutations or autocrine
FGF signaling. Inhibiting this activity significantly reduces
MMP-1 expression and blocks collagenolytic activity. These
data begin to provide one possible molecular link between the
high frequency of BRAF mutation, constitutive ERK activity,
and the development of a metastatic phenotype during mela-
noma progression.
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